Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
PR Newswire•15/11/2026•12:05 ET
7
Key Highlights
- ➤74% of weekly VK2735 participants improved at least one BMI category versus 15% placebo
- ➤VK2735 improved cardiometabolic markers, including glucose, lipids, blood pressure, and waist circumference
- ➤VK2735 delivered up to 14.7% mean weight loss after 13 weeks
- ➤Up to 88% of VK2735 patients achieved at least 10% weight loss versus 4% placebo
- ➤VANQUISH Phase 3 studies expected to be completed in 2027
Expert Statements
Brian Lian, Chief Executive Officer of Viking Therapeutics
“This important new analysis demonstrates further evidence of VK2735's potential benefits, supporting our belief that weight loss from treatment with VK2735 may improve overall cardiometabolic health.”
Brian Lian, Chief Executive Officer of Viking Therapeutics
“Nearly three-quarters of participants treated with VK2735 in the VENTURE trial improved their BMI category and treated cohorts showed improvements in key cardiometabolic measures, including blood pressure, lipids, glucose, and waist circumference, after 13 weeks.”
Brian Lian, Chief Executive Officer of Viking Therapeutics
“These findings reinforce the breadth of benefits derived from improvement in obesity severity following treatment with VK2735.”
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026 PR Newswire
VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks
Get started
Create a free account to read the full story.
